Nick Wlazlo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nick Wlazlo has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Bart J. A. Rijnders
Department of Internal Medicine, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands
2 shared publications Ada van Bruchem-Van de Scheur
Master Advanced Nursing Practice, Rotterdam University of Applied Sciences , Rotterdam
1 shared publication- Alexander Schauwvlieghe
Department of Internal Medicine, Section of Infectious Diseases, Erasmus University Medical Center, Rotterdam, The Netherlands
1 shared publication - Corné H. W. Klaassen
Department of Medical Microbiology and Infectious Diseases, Erasmus MC University Medical Center Rotterdam, Rotterdam, Netherlands
1 shared publication - Dorine Dijkshoorn-Fokker
Department of Hematology, Erasmus University Medical Center Cancer Institute , Rotterdam
1 shared publication - Franny Jongbloed
Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands
1 shared publication
Latest Publications
- Open Access
- 14 May 2026
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 34 (6)
Variability in anthracycline dose conversions and cardiotoxicity monitoring: insights from hospital pharmacists on institutional protocols in oncology practice
Purpose: Anthracycline-induced cardiotoxicity is dose-dependent, yet guidelines provide inconsistent cumulative dose thresholds and few standards for converting doses when multiple agents are used. Moreover, no formal guideline exists to unify these practices and responsibilities. Therefore, we evaluated anthracycline dosing and cardiotoxicity monitoring across Dutch hospitals to identify variability. Methods: A national cross-sectional survey was conducted among hospital pharmacists in the first quarter of 2024 in the Netherlands. Hospitals completed a 16‑item questionnaire assessing cumulative dose thresholds, equivalence factors for converting to doxorubicin‑equivalent doses, cardiac monitoring protocols and circumstances under which thresholds are exceeded. Results: Responses were received from 43 of 69 hospitals (62%). Reported cumulative dose thresholds varied widely for idarubicin (150—450 mg/m 2 ) and mitoxantrone (80—250 mg/m 2 ); equivalence factors differed more than ten‑fold between institutions. Nearly half of respondents reported exceeding recommended cumulative dose thresholds in specific clinical contexts. Cardiac monitoring was inconsistent, with 65% of hospitals not routinely measuring left ventricular ejection fraction. Moreover, multigated acquisition scans were used more often than echocardiography despite guideline preference for the latter. Conclusion: Our results reveal substantial heterogeneity in anthracycline dosing and cardiotoxicity monitoring across hospitals. Variability in equivalence factors, particularly for mitoxantrone and idarubicin, may lead to misestimation of cumulative cardiotoxic risk. These findings support the need for standardized approaches to dose conversion and improved adherence to cardiac monitoring recommendations to enhance patient safety.
- 14 May 2026
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 34 (6)
Open AccessVariability in anthracycline dose conversions and cardiotoxicity monitoring: insights from hospital pharmacists on institutional protocols in oncology practice
Purpose: Anthracycline-induced cardiotoxicity is dose-dependent, yet guidelines provide inconsistent cumulative dose thresholds and few standards for converting doses when multiple agents are used. Moreover, no formal guideline exists to unify these practices and responsibilities. Therefore, we evaluated anthracycline dosing and cardiotoxicity monitoring across Dutch hospitals to identify variability. Methods: A national cross-sectional survey was conducted among hospital pharmacists in the first quarter of 2024 in the Netherlands. Hospitals completed a 16‑item questionnaire assessing cumulative dose thresholds, equivalence factors for converting to doxorubicin‑equivalent doses, cardiac monitoring protocols and circumstances under which thresholds are exceeded. Results: Responses were received from 43 of 69 hospitals (62%). Reported cumulative dose thresholds varied widely for idarubicin (150—450 mg/m 2 ) and mitoxantrone (80—250 mg/m 2 ); equivalence factors differed more than ten‑fold between institutions. Nearly half of respondents reported exceeding recommended cumulative dose thresholds in specific clinical contexts. Cardiac monitoring was inconsistent, with 65% of hospitals not routinely measuring left ventricular ejection fraction. Moreover, multigated acquisition scans were used more often than echocardiography despite guideline preference for the latter. Conclusion: Our results reveal substantial heterogeneity in anthracycline dosing and cardiotoxicity monitoring across hospitals. Variability in equivalence factors, particularly for mitoxantrone and idarubicin, may lead to misestimation of cumulative cardiotoxic risk. These findings support the need for standardized approaches to dose conversion and improved adherence to cardiac monitoring recommendations to enhance patient safety.
- Open Access
- 18 July 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (8) , ofaf419
Limited Diagnostic and Therapeutic Value of Chest X-Rays in Hematological Patients With Febrile Neutropenia
Background: In hematological patients with febrile neutropenia, chest X-rays are frequently performed to exclude possible pulmonary infections. However, the diagnostic and therapeutic value of this imaging remains unclear. Methods: We conducted a retrospective observational cohort study over a 2-year period, examining episodes of febrile neutropenia in adult patients treated with myelosuppressive chemotherapy. Febrile episodes were categorized based on the presence (group A) or absence (group B) of respiratory symptoms. We assessed the frequency of abnormal chest X-rays and chest computed tomography (CT) scans and their impact on antimicrobial treatment decisions. Results: Of the 412 febrile episodes in 259 patients, 41.4% in group A and 16.1% in group B had an abnormal chest X-ray (P < .001). X-rays showing infiltrates were followed by chest CT in 51.5%. Antimicrobial treatment decisions were rarely based on results of X-rays: 6.9% (95% confidence interval [CI], 2.4%–15.6%) in group A and 3.4% (95% CI, 1.9%–5.7%) in group B (P = .200). In group A, however, antimicrobial treatment was more often adjusted based on an ensuing abnormal CT: 17.2% (95% CI, 9.2%–28.4%) versus 6.2% (95% CI, 4.0%–9.1%) (P = .004). Conclusions: Chest X-rays rarely influence antibiotic treatment decisions in febrile neutropenia and can probably be safely omitted, especially in patients without respiratory symptoms.
- 18 July 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (8) , ofaf419
Open AccessLimited Diagnostic and Therapeutic Value of Chest X-Rays in Hematological Patients With Febrile Neutropenia
Background: In hematological patients with febrile neutropenia, chest X-rays are frequently performed to exclude possible pulmonary infections. However, the diagnostic and therapeutic value of this imaging remains unclear. Methods: We conducted a retrospective observational cohort study over a 2-year period, examining episodes of febrile neutropenia in adult patients treated with myelosuppressive chemotherapy. Febrile episodes were categorized based on the presence (group A) or absence (group B) of respiratory symptoms. We assessed the frequency of abnormal chest X-rays and chest computed tomography (CT) scans and their impact on antimicrobial treatment decisions. Results: Of the 412 febrile episodes in 259 patients, 41.4% in group A and 16.1% in group B had an abnormal chest X-ray (P < .001). X-rays showing infiltrates were followed by chest CT in 51.5%. Antimicrobial treatment decisions were rarely based on results of X-rays: 6.9% (95% confidence interval [CI], 2.4%–15.6%) in group A and 3.4% (95% CI, 1.9%–5.7%) in group B (P = .200). In group A, however, antimicrobial treatment was more often adjusted based on an ensuing abnormal CT: 17.2% (95% CI, 9.2%–28.4%) versus 6.2% (95% CI, 4.0%–9.1%) (P = .004). Conclusions: Chest X-rays rarely influence antibiotic treatment decisions in febrile neutropenia and can probably be safely omitted, especially in patients without respiratory symptoms.
- Open Access
- 3 May 2024
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 11 (6) , ofae252
Diagnostic Value of Microbial Cell-free DNA Sequencing for Suspected Invasive Fungal Infections: A Retrospective Multicenter Cohort Study
An early diagnosis and treatment of invasive fungal disease (IFD) is associated with improved outcome, but the moderate sensitivity of noninvasive diagnostic tests makes this challenging. Invasive diagnostic procedures such as bronchoalveolar lavage (BAL) have a higher yield but are not without risk. The detection and sequencing of microbial cell-free DNA (mcfDNA) may facilitate a noninvasive diagnosis. In a prospective observational study, we collected plasma in the 120 hours preceding or following a BAL in patients with hematological malignancies suspected for a pulmonary IFD. The EORTC/MSGERC2020 criteria were used for IFD classification. Sequencing was performed by Karius (Redwood City, CA) using their Karius Test (KT) on plasma and a “research use only test” on BAL fluid if available. Cases with a probable/proven IFD were identified based on standard diagnostic tests on serum and BAL (microscopy, polymerase chain reaction, galactomannan, culture) and used to calculate the sensitivity, specificity, and additional diagnostic value of the KT. Of 106 patients enrolled, 39 (37%) had a proven/probable invasive aspergillosis, 7 (7%) a non-Aspergillus IFD, and 4 (4%) a mixed IFD. The KT detected fungal mcfDNA in 29 (28%) patients. Compared with usual diagnostic tests, the sensitivity and specificity were 44.0% (95% confidence interval [CI], 31.2–57.7) and 96.6% (95% CI, 88.5%–99.1%). Sensitivity of the KT was higher in non-Aspergillus IFD (Mucorales:2/3, Pneumocystis jirovecii: 3/5). On BAL, the sensitivity was 72.2% (95% CI, 62.1–96.3), and specificity 83.3% (95% CI, 49.1–87.5). Sequencing of mcfDNA may facilitate a noninvasive diagnosis of IFD in particular non-Aspergillus IFD. However, on plasma and similar to currently available diagnostics, it cannot be used as a “rule-out” test.
- 3 May 2024
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 11 (6) , ofae252
Open AccessDiagnostic Value of Microbial Cell-free DNA Sequencing for Suspected Invasive Fungal Infections: A Retrospective Multicenter Cohort Study
An early diagnosis and treatment of invasive fungal disease (IFD) is associated with improved outcome, but the moderate sensitivity of noninvasive diagnostic tests makes this challenging. Invasive diagnostic procedures such as bronchoalveolar lavage (BAL) have a higher yield but are not without risk. The detection and sequencing of microbial cell-free DNA (mcfDNA) may facilitate a noninvasive diagnosis. In a prospective observational study, we collected plasma in the 120 hours preceding or following a BAL in patients with hematological malignancies suspected for a pulmonary IFD. The EORTC/MSGERC2020 criteria were used for IFD classification. Sequencing was performed by Karius (Redwood City, CA) using their Karius Test (KT) on plasma and a “research use only test” on BAL fluid if available. Cases with a probable/proven IFD were identified based on standard diagnostic tests on serum and BAL (microscopy, polymerase chain reaction, galactomannan, culture) and used to calculate the sensitivity, specificity, and additional diagnostic value of the KT. Of 106 patients enrolled, 39 (37%) had a proven/probable invasive aspergillosis, 7 (7%) a non-Aspergillus IFD, and 4 (4%) a mixed IFD. The KT detected fungal mcfDNA in 29 (28%) patients. Compared with usual diagnostic tests, the sensitivity and specificity were 44.0% (95% confidence interval [CI], 31.2–57.7) and 96.6% (95% CI, 88.5%–99.1%). Sensitivity of the KT was higher in non-Aspergillus IFD (Mucorales:2/3, Pneumocystis jirovecii: 3/5). On BAL, the sensitivity was 72.2% (95% CI, 62.1–96.3), and specificity 83.3% (95% CI, 49.1–87.5). Sequencing of mcfDNA may facilitate a noninvasive diagnosis of IFD in particular non-Aspergillus IFD. However, on plasma and similar to currently available diagnostics, it cannot be used as a “rule-out” test.